ERBB3 and ovarian cancer: In malignancies such as ovarian cancer where HER3 is frequently expressed (53.4%), expression has been associated with a shorter survival time (3.31 vs. 1.8 years median survival time: low HER3 expression and HER3 over-expression, respectively) (31).